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Abstract 
Caspase recruitment domain-containing 
membrane-associated guanylate kinase, 
Carma1 initiates a unique signaling 
cascade via Bcl10 and Malt1 in NK cells. 
Carma1 deficiency results in reduced 
phosphorylation of JNK1/2 and activation 
of NF-κB that lead to impaired NK cell-
mediated cytotoxicity and cytokine 
production. However, the precise 
identities of the downstream signaling 
molecules that link Carma1 to these 
effector functions were not defined. Here 
we show, transforming growth factor β 
(TGF-β)-activated kinase, TAK1 is 
abundantly present in NK cells, and 
activation via NKG2D results in its 
phosphorylation. Lack of Carma1 
considerably reduced TAK1 
phosphorylation, demonstrating the 
dependence of TAK1 on Carma1 in 
NKG2D-mediated NK cell activations. 
Pharmacological inhibitor to TAK1 
significantly reduced NK-mediated 
cytotoxicity and its potential to generate 
IFN-γ, GM-CSF, MIP-1α, MIP-1β and 
RANTES.  Conditional in vivo 
knockdown of TAK1 in NK cells from 
Mx1Cre+TAK1fx/fx mice resulted in 
impaired NKG2D-mediated cytotoxicity 
and cytokine/chemokine production. 
Inhibition or conditional knockdown of 
TAK1 severely impaired the NKG2D-
mediated phosphorylation of ERK1/2, 
JNK1/2 and activation of NF-κB and 
AP1. Our results show that TAK1 links 
Carma1 to NK cell-mediated effector 
functions.  
 
Introduction 
TCR, BCR and NKG2D-mediated stimulation 
triggers the activation and nuclear translocation 
of NF-κB and JNK transcription factors. Several 
genes that are regulated by NF-κB and JNK are 
crucial for lymphocyte development, 
proliferation, survival, migration and effector 
functions (1). Carma1 is an adaptor protein 
that contains an N-terminal caspase recruitment 
domain (CARD) and a C-terminal 
Serine/Threonine rich domain. Carma1 is 
critical for antigen receptor-induced nuclear 
translocation of NF-κB via ubiquitination-
mediated activation of the IκB kinase (IKK) 
complex (2-4). Carma1-deficient (Carma1−/−) 
mice displayed severely impaired NF-κB 
activation, T cell development, IL-2 production 
and TCR-induced proliferation (5;6). Carma1 
deficiency resulted in a significant reduction in 
follicular (FO), marginal zone (MZ), and 
peritoneal B1 B cells (6). In addition, Carma1 
deficiency impaired BCR-induced NF-κB-
dependent proliferation of B cells and lead to a 
reduction in the basal levels of serum 
immunoglobulins (5;6). Carma1−/− mice failed 
to generate antibody responses to the T cell-
dependent and -independent antigens (7).  
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 2 
Recently, Carma1 deficiency has been shown to 
affect NK-mediated cytokine generation (8;9). 
However, a mechanistic understanding of how 
Carma1 transduces the receptor-mediated 
signaling into NK-mediated effector functions 
has yet to be determined. Multiple downstream 
effector molecules for Carma1 have been 
defined. TAK1 plays a critical role in the 
induction of transcription factors, NF-κB and 
AP1. TAK1 is a mitogen-activated kinase 
kinase kinase (MAPKKK) (10). Irrespective of 
these progresses, role of TAK1 in regulating 
effector functions and its dependence on 
Carma1 in NK cell has yet to be defined. 
 
In this study, we show that Carma1−/− NK cells 
were less effective in lysing tumor cells and 
have significantly impaired NCR1, CD244, 
NKG2D, Ly49D and NK1.1-mediated cytokine 
and chemokine production. TAK1 
phosphorylation was considerably reduced in 
the absence of Carma1. Pharmacological 
inhibition of TAK1 resulted in reduction of 
cytotoxicity and cytokine/chemokine production 
in NK cells. Conditional knockdown of TAK1 
significantly impaired NKG2D-mediated 
cytokine and chemokine production in NK cells. 
Additionally, knockdown of TAK1 moderately 
reduced NKG2D-mediated tumor lysis by NK 
cells. Collectively, our results provide important 
insights into TAK1-regulated signaling events 
in NK cells.  
Results 
 
Lack of Carma1 moderately reduces the 
natural cytotoxicity of NK cells. Carma1 
expression is critical for antigen receptor-
mediated signaling in T and B cells (11;12). 
NKG2D is ubiquitously expressed on NK cells 
and the activation through NKG2D results in 
cytotoxicity against ligand expressing target 
cells (13). Earlier studies from us and others 
have shown that ectopic expression of H60 on 
tumor cells renders them susceptible to 
NKG2D-mediated cytotoxicity (14-16). To 
assess the ability of Carma1−/− NK cells in 
mediating cytotoxicity through NKG2D 
receptor, we tested EL4 cell lines that stably 
express H60 (EL4H60) in 51Cr-release assays 
(16). These stable cell lines express either 
physiological (EL4H60-Low) or pathological 
(EL4H60-High) (Fig. 1A) levels of H60 (17). 
Parental EL4 cells were used as negative 
controls. We tested the IL-2-cultured splenic 
NK cells in cytotoxicity assays. Carma1−/− NK 
cells consistently showed reduced abilities to 
lyse both EL4H60-Low and EL4H60-High compared 
to WT (Fig. 1B). Cells that lack or have reduced 
expression of self MHC Class I molecules are 
susceptible to NK cell-mediated cytotoxicity 
(18). However, the signaling events that 
positively regulate this cytotoxicity are not fully 
understood. To test whether Carma1 plays a role 
in ‘missing-self’ recognition, we measured the 
cytotoxic potential of IL-2-activated splenic NK 
cells against RMA/S, which expresses 
significantly lower levels of MHC Class I and 
its parental RMA tumor cells. Similar to 
EL4H60, RMA/S cells were also lysed with 
lower efficiency by Carma1−/− NK cells 
compared to that of WT (Fig. 1B). A moderate 
but significant reduction in cytotoxicity could 
have been due to a defect in the Carma1-
mediated signaling pathway or due to a 
reduction in granzyme B. To exclude the later, 
we analyzed the level of granzyme B in WT and 
Carma1−/− NK cells by flow cytometry. Results 
presented in Fig. 1C indicate comparable levels 
of granzyme B between the WT and the 
knockout-derived NK cells. Thus, we conclude 
that the moderate but significant defect in 
cytotoxicity in Carma1−/− NK cells is due to a 
failure in the successful mobilization of 
cytotoxic granules. The impaired cytotoxicity 
was not due to a reduction in NKG2D 
expression levels, since it was comparable 
between WT and Carma1−/− NK cells (Fig. 1D). 
To further confirm this defect in cytotoxicity, 
we challenged the WT and Carma1−/− mice with 
double-stranded, RNA-like polyinosine-
polycytidylic acid polymer (poly I:C) that has 
been demonstrated to induce the production of 
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 3 
IFN-α and IFN-β (19). Total splenic cells from 
the poly I:C or PBS-treated mice were co-
cultured with EL4, EL4-H60High or YAC-1 
target cells for four hours. We used the cell 
surface expression of CD107a as a measure of 
cytotoxicity in CD3−NK1.1+ NK cells. Results 
show a significant reduction in the levels of 
CD107a expression in Carma1−/− NK cells 
compared to that of WT (Fig. 1E). In addition, 
we also stimulated the splenic NK cells with 
plate-bound anti-NKG2D mAb and further 
confirmed the requirement of Carma1 in NK 
cell-mediated cytotoxicity (Fig. 1F). Increase in 
CD107a expression in NK cells following co-
culture of splenocytes from PBS-treated mice 
was negligible compared to poly I:C treated 
mice (data not shown). 
 
Lack of Carma1 significantly impairs 
cytokine and chemokine production in NK 
cells. Gene transcription and production of 
inflammatory cytokines are regulated by NF-κB 
and c-Jun/AP1 transcription factors. As part of 
their innate immune response, NK cells generate 
substantial quantities of cytokines such as IFN-
γ, GM-CSF and chemokines MIP-1α, MIP-1β 
and RANTES (20). To determine the role of 
Carma1 in the generation of cytokines and 
chemokines, IL-2-cultured splenic NK cells were 
activated with titrated concentrations of plate-
bound anti-NCR1 (goat polyclonal), anti-CD244 
(2B4), anti-NKG2D (A10), anti-Ly49D (4E5) or 
anti-NK1.1 (PK136) mAbs. Supernatants were 
collected and the levels of IFN-γ, GM-CSF, 
MIP-1α, MIP-1β and RANTES were measured 
by Bioplex assays. WT NK cells produced large 
amounts of IFN-γ and GM-CSF (Fig. 2A). In 
contrast, Carma1−/− NK cells were significantly 
impaired in their ability to produce IFN-γ and 
GM-CSF (Fig. 2A). Similar to these results, 
Carma1−/− NK cells also produced significantly 
lower amounts of chemokines, MIP-1α, MIP-1β 
and RANTES compared to the WT. Thus, 
Carma1 is a critical regulator of signaling events 
that are initiated via NCR1/CD3, CD244/SAP, 
NKG2D/DAP12, Ly49D/DAP12 or 
NK1.1/FcRγ  complexes. Activation by the 
mitogenic antibodies were specific since neither 
no-stimulation nor respective isotype antibody 
controls failed to elicit significant levels of these 
cytokines or chemokines (Fig. 2A). To 
determine whether this is a generalized hypo-
responsiveness or exclusive defect associated 
with ITAM-containing activation receptors, we 
stimulated NK cells with IL-12, IL-18 or both. 
IL-12 and IL-18-mediated activation utilizes the 
JAK/STAT pathway and does not involve 
Carma1 for downstream signaling. WT and 
Carma1−/−-derived NK cells responded equally 
well to IL-12 and IL-18-mediated activation 
(Fig. 2B). This demonstrates that Carma1−/− NK 
cells are fully capable of responding through 
their cytokine receptors. The substantial 
reduction could be due to the inabilities of the 
Carma1−/− NK cells to produce cytokines or due 
to a defect in cytokine secretion. To distinguish 
between these two possibilities, we quantified 
the amounts of IFN-γ-encoding mRNA before 
and after plate-bound anti-NKG2D mAb 
activation. Fig. 2C shows a significantly less 
copy number of IFN-γ-encoding mRNA in 
spleen-derived Carma1−/− NK cells. One of the 
potential reasons for the defect in the production 
of cytokine or chemokine from Carma1−/− NK 
cells may be a lower responsiveness to IL-2 
during the in vitro culture. To further analyze 
this possibility, we co-cultured the total splenic 
cells from poly I:C treated mice with EL4, EL4-
H60High or YAC-1 target cells for twelve hours 
and quantified the levels of intracellular IFN-γ 
in CD3−NK1.1+ NK cells. Results presented in 
Fig. 2D show a significant reduction in the 
percentages of IFN-γ NK cells in Carma1−/− 
compared to that of WT. Thus, we conclude that 
Carma1 plays an obligatory role in the 
transcription of cytokine and chemokine genes 
and its absence significantly reduces the ability 
of NK cells to produce these soluble mediators. 
 
Lack of Carma1 reduces NKG2D-mediated 
TAK1 phosphorylation, which leads to 
impaired JNK1/2 and NF-κB activation. 
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 4 
Earlier studies have shown that activation of 
MAPK are required for cytotoxic granule 
release and cytokine production in murine and 
human NK cells (21-24). To determine the role 
of Carma1 in NKG2D-mediated activation, we 
quantified the levels of MAPK phosphorylation 
and NF-κB activation in NK cells. 
Phosphorylation levels of ERK1/2 and p38 were 
comparable between WT and Carma1−/− NK 
cells (Fig. 3A and C). However, the level of 
JNK1/2 phosphorylation was considerably 
reduced in Carma1−/− NK cells (Fig. 3A and C). 
Cells were harvested at different time points of 
activation and their nuclear protein extracts 
were analyzed for the level of NF-κB activation 
in electrophoretic mobility shift assays (EMSA). 
After anti-NKG2D mAb-mediated activation, 
NF-κB was abundantly translocated into the   
nucleus in the WT; but, not in the Carma1−/− 
NK cells (Fig. 3B and C). 
  
TAK1 is a member of MAPKKK family and a 
key modulator of NF-κB and JNK that regulates 
proinflammatory signaling in multiple immune 
cell types (25). TAK1 regulates the activation of 
p38 and JNK1/2 through the phosphorylation of 
MKK3/6 (26) and MKK4 (27), respectively. 
Activation of c-Jun/AP1 is regulated by JNK1/2 
(28). Since JNK1/2 is known to play important 
role in the cytotoxic granule release, we 
hypothesized that lack of Carma1 reduces 
TAK1 phosphorylation, which could be 
primarily responsible for the impairment in NK 
cytotoxicity. Activation and phosphorylation of 
TAK1 downstream of NKG2D receptor in NK 
cell is yet to be defined. Both fresh and IL-2-
cultured NK cells contained ample amounts of 
TAK1 (Fig. 3D and E). Earlier studies have 
shown that phosphorylation of Carma1 in the 
PRD domain by PKC-β and PKC-θ allows 
Carma1 to form a signalosome with Bcl10, 
MALT1, TRAF2, TAK1 and IKKγ (NEMO) 
(29-31). Other studies have indicated that TAK1 
can be activated via TRAF2 or TRAF6, 
independent of Carma1 (32). TAK1 also 
regulates the NF-κB pathway through its 
interaction with TRAF6 and by phosphorylating 
the NF-κB-inducing kinase (NIK) (33). 
Autophosphorylation at threonines 184 and 187 
with the help of TAB1 is critical for the kinase 
function of TAK1. To determine the role of 
Carma1 in TAK1 activation, we stimulated IL-
2-cultured NK cells from WT and Carma1−/− 
mice with plate-bound anti-NKG2D mAb. Fig. 
3F and G indicates abundant phosphorylation of 
TAK1 in the WT NK cells, which peaked at 20 
min after activation. However, its 
phosphorylation in Carma1−/− NK cells was 
considerably reduced. Thus, our results indicate 
that TAK1 is a critical link between Carma1 and 
JNK1/2 (c-Jun/AP1) or NF-κB activations 
downstream of NKG2D in NK cells.  
 
Inhibition of the kinase activity of TAK1 
reduces NK cell effector functions. To 
establish a functional role of TAK1 in NK cells, 
we used a pharmacological compound to inhibit 
the kinase activity of TAK1. IL-2-cultured NK 
cells were pretreated with titrating 
concentrations of a naturally occurring fungal 
resorcylic acid lactone, 5Z-7-oxo-zeaenol  for 1 
h at 37o C (34). 5Z-7-oxo-zeaenol specifically 
inhibits the catalytic activity of TAK1 by 
interacting with the ATP-binding site. Pretreated 
NK cells were tested for their ability to mediate 
cytotoxicity against EL4, EL4H60-High, RMA/S 
and YAC1 cells. Effector to target ratio was 
kept at 20:1. Our results presented in Fig. 3H, 
demonstrates that inhibition of TAK1 activation 
with 5Z-7-oxo-zeaenol significantly affected the 
ability of NK cells to lyse EL4H60-High, YAC-1 
and RMA/S target cells. Thus, our results 
implicate TAK1 in the cytotoxic granule release 
by NK cells. Next, we analyzed the role of 
TAK1 in NK cell-mediated cytokine or 
chemokine production. 5Z-7-oxo-zeaenol-
pretreated WT NK cells were stimulated with 
plate-bound mAbs to NKG2D, NCR1, Ly49D 
and CD244. NKG2D, NCR1 and CD244 are 
ubiquitously expressed on all murine NK cells. 
Ly49D is expressed in about 50% of the NK 
cells. Pretreatment of NK cells with TAK1 
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 5 
inhibitor significantly reduced their ability to 
generate cytokines and chemokines (Fig. 3I). 
5Z-7-oxo-zeaenol was tested between the ranges 
of 4 µM to 0.5 µM. Even at the lowest 
concentrations of the inhibitor, generation of 
cytokines and chemokines were significantly 
reduced. Analyses of the viability of 5Z-7-oxo-
zeaenol pretreated NK cells revealed that the 
highest concentration used (4 µM) in these 
assays did not cause any detectable levels of cell 
death. Further, analysis of IFN-γ production in 
TAK1 inhibitor-pretreated NK cells following 
IL-12- and IL-18-mediated activation revealed 
that TAK1 inhibition did not affect the cytokine 
production, thus precluding the non-specific 
effects of this drug (Fig. 3J).  
 
TAK1 is essential for NKG2D-mediated 
ERK1/2, JNK1/2 phosphorylation and NF-κB 
activation. To further confirm the molecular 
mechanism by which TAK1 regulates the NK 
cell effector functions, we analyzed the status of 
ERK1/2, JNK1/2 and NF-κB activations in 5Z-
7-oxo-zeaenol-pretreated (0.5 µM) NK cells. 
Pretreatment with this inhibitor considerably 
reduced both the ERK1/2 and JNK1/2 
phosphorylation compared to that of untreated 
NK cells (Fig. 4A). The mechanism by which 
ERK1/2 phosphorylation is reduced after 5Z-7-
oxo-zeaenol treatment in NK cells is not clear 
and requires additional investigations. 
Activation of NK cells through NKG2D 
receptor resulted in the nuclear translocation of 
NF-κB in the untreated NK cells (Fig. 4B). 
However, pretreatment with 5Z-7-oxo-zeaenol 
reduced the activation and nuclear translocation 
of NF-κB. To precisely determine the role of 
JNK1/2 in NKG2D-mediated effector functions, 
NK cells were pretreated with SP600125, a 
pharmacological inhibitor for JNK1/2 and tested 
for their ability to kill EL4H60-High tumor cells. 
JNK1/2 inhibition significantly reduced the 
cytotoxicity of NK cells against EL4H60-High 
tumor cells (Fig. 4C) at an E:T ratio of 20:1. 
Previously, it has been shown that in addition to 
ERK1/2, JNK1/2 activation downstream of 
NKG2D is also critical for NK cell-mediated 
cytotoxicity (23). Additionally, JNK1/2 
inhibitor also reduced the percentage of 
intracellular IFN-γ+ NK cells following anti-
NKG2D-mediated activation (Fig. 4D). Based 
on these results, we conclude that TAK1 is an 
essential intermediate downstream of Carma1 
and the functional impairment in Carma1−/− NK 
cells is due to a reduction in the phosphorylation 
levels of TAK1 that led to a decrease in JNK1/2 
and NF-κB activations.  
 
Conditional knockdown of TAK1 
significantly reduces NKG2D-mediated 
effector functions. To confirm that TAK1 
indeed regulates NKG2D-mediated effector 
functions via JNK1/2 and NF-κB/AP1, we used 
a mouse model where TAK1 could be 
conditionally knocked down. By crossing 
Mx1Cre mice with TAK1fx/fx mice (35), 
interferon-inducible TAK1 knockdown mice 
were generated (36). Splenic NK cells from 
poly-I:C-treated TAK1fx/fx or  Mx1Cre+TAK1fx/fx 
mice were cultured with IL-2. As expected, 
TAK1 expression was considerably reduced in 
poly-I:C-treated NK cells obtained from 
Mx1Cre+TAK1fx/fx compared to TAK1fx/fx mice 
(Fig. 5A). Functional analyses of TAK1fx/fx and 
Mx1Cre+TAK1fx/fx NK cells revealed that 
cytotoxicity against EL4H60-High tumor cells was 
moderately but significantly reduced in the 
Mx1Cre+TAK1fx/fx NK cells (Fig. 5B). Further, 
analyses of LAMP1 (CD107a) surface 
expression as an independent measure of 
cytotoxicity also revealed a reduction in the 
TAK1-deficient NK cells (Fig. 5C). Based on 
these observations, we conclude that the NK 
cell-mediated cytotoxicity can be in part 
regulated by TAK1.  
 
Next, we analyzed the ability of 
Mx1Cre+TAK1fx/fx NK cells to produce cytokines 
and chemokines through NKG2D-mediated 
activation. Similar to Carma1-deficiency, 
knockdown of TAK1 significantly reduced the 
production of IFN-γ, GM-CSF, IL-10, TNF-α, 
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 6 
MIP-1α, MIP-1β and RANTES (Fig. 5D). Our 
data presented in Fig. 2B indicated that IL-12 
and IL-18-mediated cytokine and chemokine 
production did not require Carma1. To 
investigate the role of TAK1 in cytokine 
receptor-mediated activation, we stimulated NK 
cells from TAK1fx/fx and Mx1Cre+TAK1fx/fx mice 
with IL-12 and IL-18. Production of IFN-γ (Fig. 
5E) was comparable between NK cells from 
TAK1fx/fx and Mx1Cre+TAK1fx/fx mice. 
Intracellular staining for IFN-γ revealed a 
similar pattern where NKG2D- but not IL-12- 
and IL-18-mediated IFN-γ production was 
defective in the Mx1Cre+TAK1fx/fx NK cells 
(Fig. 5F). Analyses of IFN-γ-encoding mRNA 
levels following NKG2D-mediated activation in 
TAK1fx/fx and Mx1Cre+TAK1fx/fx NK cells 
indicated that the reduction occurred at the 
transcriptional level (Fig. 5G). Collectively, 
these results demonstrate that TAK1 can 
regulate both the natural cytotoxicity and 
cytokine production in NK cells.  
 
Lack of TAK1 impairs NKG2D-mediated 
ERK1/2, JNK1/2, NF-κB and AP1 activation. 
Next, we determined the downstream signaling 
events regulated by TAK1 in NKG2D-mediated 
activation. Towards this, we analyzed the 
ERK1/2 and JNK1/2 phosphorylation in NK 
cells from TAK1fx/fx and Mx1Cre+TAK1fx/fx. IL-2-
cultured were stimulated with plate-bound anti-
NKG2D antibody (5µg/ml) for 30 min, 
transferred to chamber-slides and stained for 
phospho or total proteins. Activated cells were 
analyzed through confocal microscopy to 
determine the levels of ERK1/2 and JNK1/2 
phosphorylations. Data presented in Fig. 6A 
demonstrate that activation of TAK1fx/fx mice-
derived NK cells resulted in abundant 
phosphorylation of ERK1/2 and JNK1/2. 
However, a similar activation of NK cells from 
Mx1Cre+TAK1fx/fx mice resulted in reduced 
ERK1/2 or JNK1/2 protein phosphorylations.  
To obtain statistical validation of these 
observations, we quantified fluorescence 
intensity in individual NK cells. A single 
reference line (RO1) was drawn across each NK 
cell and an average of the fluorescence intensity 
was calculated and presented in Fig. 6B. These 
analyses further confirmed a significant 
reduction in ERK1/2 and JNK1/2 
phosphorylation in NK cells from 
Mx1Cre+TAK1fx/fx mice. This is not due to a 
reduction in the total ERK1/2 or JNK1/2 
proteins, since their fluorescence intensities 
were comparable between the TAK1fx/fx and 
Mx1Cre+TAK1fx/fx mice-derived NK cells (Fig. 
6A and B). Next, we analyzed the status of NF-
κB and AP1 after NKG2D-mediated activation. 
Our results show NKG2D-mediated NF-κB 
activation was considerably reduced in NK cells 
from Mx1Cre+TAK1fx/fx mice (Fig. 6C). 
Additionally, the activation of AP1 (Fig. 6D) 
was also reduced in Mx1Cre+TAK1fx/fx NK cells 
following NKG2D cross-linking. These results 
reveal that TAK1 is critical for NKG2D-
mediated activation of NF-κB and AP1 in NK 
cells.  Quantification of these activated proteins 
further confirmed the obligatory role of TAK1 
in NKG2D-mediated activation in NK cells 
(Fig. 6E). We conclude that TAK1 is a critical 
intermediate between Carma1 and NK-mediated 
effector functions.  
 
Discussion 
 
In this study, we have determined the role of 
TAK1 in NK-mediated effector functions. 
Oligomerized Carma1 recruits multiple 
signaling components including TAK1 to 
activate NF-κB and JNK1/2. By acting as both 
IKK kinase and a JNK kinase kinase, TAK1 
links Carma1 to inducible transcription factors 
(25). TAK1 plays a critical role as a kinase for 
IKKβ, which leads to IκB phosphorylation (25). 
Independently, downstream of MKK6, TAK1 
can also phosphorylate JNK1/2 leading to AP1 
activation (c-Jun/AP1 heterodimer) (37). 
Evidence for this is provided from the AP1-
dependent cytokine gene transcription in 
FcγRIIIA-stimulated human NK cells (38). In 
this study, using Carma1−/− and 
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 7 
Mx1Cre+TAK1fx/fx mice, we defined that TAK1 
is an essential molecular link between Carma1 
and NK cell-mediated cytotoxicity and 
proinflammatory cytokine production. Since the 
development and maturation of NK cells in 
Carma1−/− mice were normal, we conclude that 
the functional inabilities were due to 
impairments in downstream signaling pathways 
and not due to inappropriate development, 
differentiation or homeostasis of NK cells. 
 
NK cells recognize tumor cells through multiple 
receptor-ligand interactions. Lack of Carma1 or 
knockdown of TAK1 moderately yet 
significantly reduced the NK cytotoxicity 
against tumor cells. Moderate but not a 
complete reduction in cytotoxic potentials of 
Carma1−/− and Mx1Cre+TAK1fx/fx  ΝΚ cells 
indicate that these cells do not entirely depend 
on the Carma1/TAK1 pathway to mediate this 
effector function. As demonstrated by earlier 
studies NK cytotoxicity may also depend on the 
Vav-1-mediated activation of JNK1/2, ERK1/2 
and p38 (39;40). Limited defects in the 
cytotoxic potentials of Carma1−/− or 
Mx1Cre+TAK1fx/fx mice-derived NK cells could 
be due to impairments in transport and release 
of cytotoxic granules.  This notion is 
corroborated with the recent observations in 
NKG2D-expressing human NKL cell line, 
where inhibition of JNK1/2 activity resulted in 
the impaired movement of microtubule 
organizing center (MTOC), granzyme B and 
paxillin to the immune synapse (23). Our 
present findings are different from our earlier 
observations with Bcl10−/−  NK cells, where the 
NK-mediated cytotoxicity was not affected (41). 
One possible explanation is the ability of 
Carma1 to mediate Bcl10-independent 
functions, where Carma1 has been shown to 
recruit MALT1 in the absence of Bcl10 (42). 
Thus, we predict Carma1 and TAK1 but not 
Bcl10 to play an essential role in the 
cytotoxicity of NK cells.  
 
NK cells generate inflammatory cytokines and 
chemokines as part of innate immunity. 
Absence of Carma1 in NK cells significantly 
reduced cytokine and chemokine generation 
mediated via NCR1, CD244, NKG2D, Ly49D 
and NK1.1 receptors. In addition, conditional 
knockdown of TAK1 or the use of TAK1 
inhibitor, 5Z-7-oxo-zeaenol resulted in similar 
reductions in the production of IFN-γ, GM-CSF, 
IL-10, TNF-α, MIP-1α, MIP-1β and RANTES. 
Reductions in the IFN-γ-encoding mRNA after 
NKG2D-mediated activation indicates that this 
defect occurs at the transcriptional level in both 
Carma1−/− and Mx1Cre+TAK1fx/fx-derived NK 
cells. Nevertheless, these results also give 
credence that lack of Carma1 or TAK1 results in 
the generation of hyporesponsive NK cells. To 
investigate this hypothesis, we used 
proinflammatory cytokines IL-12 and IL-18 to 
stimulate NK cells. These cytokines mediate 
signaling events that are distinct from that of 
YINM or ITAM-containing receptor-mediated 
activations. IL-12 and IL-18 utilize Tyk2/Jak2-
mediated STAT4 phosphorylation to induce 
IFN-γ generation in NK cells (43;44). Indeed, 
stimulation with IL-12 and IL-18 resulted in 
normal levels of, GM-CSF, MIP-1α, MIP-1β 
and RANTES from Carma1−/− and  IFN-γ from 
Mx1Cre+TAK1fx/fx ΝΚ cells. Thus, YINM- or 
ITAM-independent pathways are fully 
operational in Carma1−/− and Mx1Cre+TAK1fx/fx 
 ΝΚ cells refuting the possibility of global 
unresponsiveness. Additionally, in vivo 
stimulation of NK cells via type I IFNs (α and 
β) using poly I:C, demonstrates that the defects 
in cytokine and chemokine production is not 
due to an inability of Carma1−/− NK cells to 
respond to IL-2 under the in vitro culture 
conditions that were used to generate LAK cells. 
 
Molecular mechanisms by which the production 
of inflammatory cytokines are regulated in NK 
cells are emerging (23;45). NKG2D and Ly49D 
recruit two distinct adaptor proteins to transduce 
activation signals (46-48). One of these adaptor 
proteins, DAP10, with a YINM motif recruits 
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PI-3K (49). The second adaptor molecule 
DAP12 with an ITAM motif associates with 
Syk and ZAP70 (50). NK1.1 recruits FcRγ to 
mediate its signal (51). NCR1 (NKp46) uses 
CD3ζ (52). CD244 belongs to CD2 family and 
utilizes an immunoreceptor tyrosine-based 
switch motif (ITSM) to recruit signaling 
lymphocyte activation molecule–associated 
protein (SAP) (53).  
 
Following these receptor-mediated activations, 
TAK1 is recruited to the 
Carma1/Bcl10/Malt1/TRAF6 or 
Carma1/Malt1/TRAF6 signalosomes (42;54). 
Reduction in the TAK1 phosphorylation in the 
Carma1−/− NK cells following NKG2D-
mediated activation demonstrates an obligatory 
role for Carma1 in TAK1 recruitment to the 
signalosome and downstream signaling. Thus, 
an impaired phosphorylation of TAK1 in the 
Carma1−/− NK cells provides the mechanistic 
explanation for the reduced levels of JNK1/2 
phosphorylation and NF-κB nuclear 
translocation in these cells. This notion is 
further confirmed by the fact that TAK1 is 
critical for JNK1/2 and NF-κB activation 
downstream of both TCR and BCR (10). 
Similarly, conditional knockdown of TAK1 in 
Mx1Cre+TAK1fx/fx ΝΚ cells (or use of 5Z-7-oxo-
zeaenol) resulted in considerable reduction in 
the phosphorylation of JNK1/2 and NF-κB 
activation. Moreover, knockdown of TAK1 in 
NK cells resulted in the reduction of AP1 
activation and ERK1/2 phosphorylation. 
Compared to NK cell cytotoxicity, a near 
complete reduction in cytokine and chemokine 
production following pretreatment with the 
TAK1 inhibitor, 5Z-7-oxo-zeaenol or 
knockdown of TAK1 indicates Carma1 via 
TAK1 mediates NF-κB and JNK1/2 activations. 
MAPKs such as ERK1/2, JNK1/2, and the p38 
are potential downstream targets for multiple 
NK cell activation receptors (55). This indicates 
that JNK1/2 are critical downstream effectors of 
Carma1 when NK cells are activated through 
NKG2D. Our study also shows that lack of 
Carma1 did not affect the phosphorylation of 
either p38 or ERK1/2. However, inhibition or 
knockdown of TAK1 did affect the overall 
phosphorylation levels of ERK1/2. Presently, 
we do not have a mechanistic explanation for 
how ERK1/2 phosphorylations are regulated by 
TAK1. Together, we conclude that TAK1 is a 
critical molecular link between Carma1 and 
cytotoxic granule release or cytokine/chemokine 
gene transcriptions in NK cells.  
 
Materials/Methods 
 
Mice and Cell lines. Carma1−/− and WT mice 
have been back crossed to C57BL/6 for eleven 
generations and were described earlier (5). 
Interferon-inducible TAK1 knockdown mice 
were generated (36) by crossing Mx1Cre mice 
(Jackson Laboratory, Bar Harbor, MN) with 
TAK1fx/fx mice (35), and backcrossing the 
resultant off springs. All mice used in this study 
were maintained in pathogen-free conditions at 
the Biological Resource Center (BRC) at the 
Medical College of Wisconsin (MCW), 
Milwaukee, WI or at the Loyola University 
Medical Center, Maywood, IL; and were used 
between 6-12 weeks of age.  All the animal 
protocols used were approved by the animal 
facilities of the respective institutions. 
Interferon-inducible TAK1 knockdown 
Mx1Cre+TAK1fx/fx mice and control TAK1fx/fx 
mice were injected with 5 µg/g body weight of 
poly I:C on day 1 and day 3 to induce TAK1 
knockdown. Spleens of these treated mice were 
collected on day 4 (36). EL4, EL4H60-Low, 
EL4H60-High, RMA, RMA/S and YAC1 cells and 
their culture conditions were as described 
(16;56).  
 
NK cell preparation. NK cells were purified as 
previously described (57). Briefly, single cell 
suspensions from different organs were passed 
through nylon wool columns to deplete adherent 
populations consisting of B cells and 
macrophages. Nylon wool-non-adherent cells 
were cultured with 1000 U/ml of IL-2 (NCI-
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BRB-Preclinical Repository, Maryland, MD). 
Purity of the NK cultures was checked and 
preparations with more than 90% of NK1.1+ 
cells were used.  
 
Flow cytometry. Single cell preparations were 
stained with fluorescent-labeled mAbs as 
described (16). Antibodies for NK1.1 (PK136), 
CD3ε (145-2C11), NKG2D (A10), anti-CD244 
(244F4) and anti-granzyme B (16G6) were 
obtained from e-Bioscience (San Diego, CA). 
Anti-H60a (205326) was obtained from R&D 
Systems (Minneapolis, MN). Anti-Ly49D was 
obtained from BD Pharmingen (San Jose, CA). 
Anti-NK1.1 secreting hybridoma clone (PK136) 
was obtained from ATCC and used. NK cells 
were stained in 1% FCS-PBS with appropriate 
antibodies (16). One million events were 
analyzed for each sample. Standard flow 
cytometry analyses were performed in LSR-II 
and analyzed with FACSDiva software (Becton 
Dickinson, CA).  
 
NK cell effector functions following poly I:C-
mediated activation in vivo. Poly I:C-mediated 
activation of NK cells in vivo. Wild type and 
Carma1−/− mice were injected with Poly I:C 
(250 µg) or PBS, intra venally. After 18 h, a 
single cell suspension of the spleen was 
prepared. Splenocytes were co-cultured with 
EL4, EL4H60-High or YAC1 at the rate of 1 
million effector cells to 0.5 million target cells. 
Intracellular IFN-γ staining was performed after 
12 h of co-culture. CD107a surface staining was 
performed after 4 h of co-culture. CD107a 
surface expression was also determined 
following plate-bound anti-NKG2D antibody-
mediated activation. 
 
Cytotoxicity assays. NK-mediated cytotoxicity 
was quantified using 51Chromium (51Cr)-labeled 
target cells (58) at varied Effector : Target ratio 
(E:T Ratio). Percent specific lysis was 
calculated using amounts of absolute, 
spontaneous and experimental 51Cr-release from 
target cells. 
 
Quantification of cytokines, chemokines and 
LAMP1 expression. IL-2-cultured, Fc-blocked 
NK cells were activated with 5 µg/ml of plate-
bound mitogenic antibodies and their culture 
supernatants analyzed in a Bioplex assay (Bio-
Rad, Richmond, CA). Intracellular IFN-γ was 
quantified as previously described (59). Briefly, 
Fc-blocked NK cells were activated with plate-
bound mAbs. After 16 h cells were stained for 
surface NK1.1, fixed, permeabilized and stained 
for intracellular IFN-γ using PE-conjugated anti-
IFN-γ mAb. For inhibitor assays, NK cells were 
incubated for 1 h with varying concentrations of 
5Z-7-oxo-zeaenol, washed and added into anti-
NKG2D mAb-coated plates. After 18 h, 
cytokines and chemokines were quantified. IL-
2-cultured NK cells were treated with IL-12, IL-
18 or both for 18 h and the supernatants were 
analyzed for the presence of indicated cytokines 
and chemokines. For quantifying IFN-γ-
encoding mRNA, NK cells were activated for 6 
h and harvested. RNA was extracted using 
RNeasy Mini Kit (Qiagen, Valencia, CA). Real-
time PCR was performed by using a previously 
published SYBR green protocol with an 
ABI7900 HT thermal cycler (60;61). For 
quantifying granule release, NK cells were 
activated with anti-NKG2D mAb and cultured 
in the presence of monensin (1:1000) and Alexa 
Fluor 488-conjugated anti-CD107a for 4 h. 
Cells were washed and stained for surface CD3 
and NK1.1. CD107a (LAMP1) surface 
expression was analyzed by flow cytometry. 
 
Western blotting. 10 µg of whole-cell lysate 
were resolved using 10 % SDS-PAGE gels, 
transferred to PVDF membranes and probed 
with indicated antibodies (12). Antibodies 
against TAK1 (upstate, Lake Placid, NY), 
phospho-TAK1 (Thr184/187), total JNK1/2 
(clone 56G8), phospho-JNK 1/2 (T183/Y185, 
clone 98-F2), total ERK1/2 and phospho-
ERK1/2 (T202/Y204, clone D13.14.4E), total 
p38 and phospho-p38 (Thr180/Tyr182, clone 
3D7, Cell Signaling, Boston, MA) and anti-actin 
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(Boehringer Mannheim, Germany) were used 
and signals were detected using ECL kit (GE 
Healthcare, Piscataway, NJ). The fold changes 
in the MAP kinase phosphorylation following 
NKG2D-mediated activation were calculated 
and compared. The band intensity of phospho-
protein was normalized against the respective 
total protein. The fold change in 
phosphorylation following 5, 20 or 60 min of 
activation was calculated using these 
normalized values by comparing it to that of 
unstimulated lanes. 
 
Confocal microscopy. NK cells were activated 
with plate-bound anti-NKG2D mAbs for 30 min 
at 37o C. Activated NK cells were harvested and 
seeded in poly-L-lysine coated chamber slides. 
Unstimulated NK cells were used as controls. 
After 1 h incubation at room temperature, cells 
were stained with Hoechst 33342. The cells 
were washed and fixed with ice cold methanol 
and permeabilized with 0.1% Triton X-100 in 
3% BSA. After blocking with 70% normal goat 
serum, cells were incubated overnight with anti-
phospho JNK1/2 (T183/Y185, clone 98-F2), 
anti-phospho ERK1/2 (T202/Y204, clone 
D13.14.4E), total JNK1/2 (Clone 56G8) and 
total ERK1/2 antibodies (Cell Signaling 
Technology, Danvers, MA). The cells were 
washed and incubated with donkey anti-rabbit 
Alexa Fluor 488 antibody (Invitrogen, 
Piscataway, NJ) for one h. Phosphorylation of 
JNK1/2 and ERK1/2 were analyzed using 
confocal microscopy. 
 
Electrophoretic mobility shift assays. IL-2-
cultured NK cells were activated with plate-
bound anti-NKG2D mAb (A10). NK cells (1 × 
106) were lysed and nuclear protein extracts 
generated using NE-PER reagent (Pierce Inc, 
Rockford, IL). 2.5 µg of the nuclear protein 
extract was used in a binding reaction with 1× 
binding buffer, 2.5% glycerol, 5mM MgCl2, 50 
ng/ul poly (dI.dC) and 0.05% NP40 (LightShift 
EMSA optimization and control kit, Pierce, 
Rockford, IL). Biotin end-labeled duplex 
oligonucleotide probes for NF-κB (forward 
5ˊAGT TGA GGG GACTTT CCC AGG 
C/3Bio-3ˊ and reverse 5ˊGCCTGG GAA AGT 
CCC CTC AACT/3Bio/-3ˊ) were added to the 
reaction mix at a final concentration of 2.0 
ng/20 µl reaction mix. After 20 min, 5 µl of 5× 
loading buffer was added to the reaction mix 
and the samples were resolved in a 6% 
polyacrylamide gel and transferred to nylon 
membrane. The protein-DNA probe complexes 
were cross-linked with a UV lamp (254 nm, 120 
mJ/cm2). NF-κB specific bands were detected 
using streptavidin-horseradish peroxidase 
conjugate in a chemiluminescence assay 
(LightShift chemiluminescent EMSA kit, Pierce 
Inc. Rockford, IL). A similar assay was 
performed to detect the transcription factor, AP1 
using biotin end-labeled duplex oligonucleotide 
probes (forward 5ˊ -/5Biosg/CGC TTG ATG 
ACT CAG CCG GAA-3ˊ and reverse 5ˊ-
/5Biosg/TTC CGG CTG AGT CAT CAA 
GCG-3ˊ).  
 
Statistical analyses. Statistical analyses were 
performed by two-tailed, unpaired, Student’s t-
test. P values of ≤ 0.05 were considered 
significant. 
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Figure Legends 
 
Fig. 1. NK cell-mediated cytotoxicity is impaired in Carma1−/− NK cells. (A) Levels of H60 
expression in stable EL4 transfectants as tested by anti-H60 antibody. (B) IL-2-activated splenic NK 
cells were tested against 51Cr-labeled EL4, EL4H60-Low, EL4H60-High and RMA/S target cells at the 
indicated E:T ratios. (C) Expression of granzyme B in IL-2-activated WT and Carma1−/− NK cells. 
NK cells were stained for NK1.1 and CD3, fixed, permeabilized and stained for intracellular 
granzyme B. CD3−NK1.1+ cells were gated and shown. (D) Expression levels of NKG2D or Ly49D 
activation receptors in WT and Carma1−/− NK cells. (E) Ex vivo NK cell cytotoxicity against EL4, 
EL4H60-High and YAC1 after in vivo poly I:C treatment was measured by surface staining for CD107a 
(LAMP1) in CD3−NK1.1+ cells following co-culture with the target cells. Mean ± SD of the 
percentage CD107a+ NK cells are shown. (F) Surface expression of CD107a in anti-NKG2D mAb 
activated NK cells following in vivo poly I:C treatment. Mean ± SD of the percentage CD107a+ NK 
cells are shown. Data shown in A-D are representative or averages of 6-8 mice in each category and 
representatives of three independent experiments. Data shown in E and F are representative of two 
independent experiments. 
 
 
Fig. 2. Quantification of IFN-γ, GM-CSF, MIP-1α, MIP-1β and RANTES in culture supernatants 
following (A) receptor- or (B) IL-12- and IL-18-mediated activations, in Bioplex assays. Activation 
with isotype antibodies was performed and one representative control (Hamster IgG1) is shown. (C) 
IFN-γ-encoding transcripts in anti-NKG2D mAb-stimulated NK cells.  Data shown in A-C are 
representative or averages ± SD of 6-8 mice in each category and representatives of three 
independent experiments. (D) Ex vivo IFN-γ production in NK cells from mice treated with poly I:C 
were measured after co-culturing with EL4, EL4H60-High and YAC1 cells. Cytokine production was 
measured by intracellular staining for IFN-γ in CD3−NK1.1+ cells. Data shown in D is representative 
of two independent experiments. Mean ± SD of the percentage IFN-γ+ NK cells are shown. 
 
Fig. 3. TAK1 is a critical intermediate in Carma1-mediated NK cell activation and function. IL-2-
activated splenic NK cells were derived from WT and Carma1−/−  mice. These NK cells were 
activated with plate-bound anti-NKG2D and analyzed for various signaling events downstream of 
NKG2D. (A) Phosphorylations of ERK1/2, JNK1/2 and p38. (B) Quantification of NF-κB in the 
nuclear extract after NKG2D-mediated activation. (C) Fold change in MAP kinase phosphorylation 
and nuclear translocation of NF-κB were compared between WT and Carma1−/−  NK cells. (D) 
TAK1 protein expression in ex vivo and IL-2-cultured NK cells. (E) Fold change in TAK1 
expression levels in ex vivo and IL-2-cultured NK cells. TAK1 expression was normalized with actin 
expression. (F) Phosphorylation of TAK1 after NKG2D-mediated activation. (G) Fold change in 
TAK1 phosphorylation were compared between WT and Carma1−/−  NK cells. One representative 
experiment out of 3 is shown in A-G. (H) NK-mediated cytotoxicity after 5Z-7-oxo-zeaenol 
treatment. Wild type NK cells were treated with 5Z-7-oxo-zeaenol that specifically inhibits the 
kinase activity of TAK1. (I) Cytokine and chemokine production in WT NK cells that were 
pretreated with TAK1 inhibitor. (J) IFN-γ production following IL-12- and IL-18-mediated 
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activation in WT NK cells pretreated with TAK1 inhibitor. Data presented are averages obtained 
from 3 mice and a representative of three independent experiments.  
 
Fig. 4.  TAK1 regulates signaling events and effector functions downstream of NKG2D in NK cells. 
WT NK cells were treated with 5Z-7-oxo-zeaenol that specifically inhibits the kinase activity of 
TAK1. Pretreated and untreated NK cells were activated with plate-bound anti-NKG2D mAb and 
analyzed for downstream signaling events.  (A) Phosphorylation of ERK1/2 and JNK1/2.  Fold 
change in MAP kinase phosphorylation were compared between WT and Carma1−/−  NK cells and 
are shown in the bottom panel. (B) Quantification of NF-κB in the nuclear extract after NKG2D-
mediated activation. WT NK cells were treated with SP600125, a specific inhibitor for JNK1/2. 
Untreated and inhibitor pretreated WT NK cells were analyzed for NKG2D-mediated (C) 
cytotoxicity and (D) IFN-γ production. 
 
Fig. 5. Conditional knockdown of TAK1 gene impairs NKG2D-mediated NK cell effector functions. 
(A) Poly I:C treatment induces the conditional knockdown of TAK1 gene in Mx1Cre+TAK1fx/fx but 
not in TAK1fx/fx-derived NK cells. IL-2-cultured NK cells were analyzed for TAK1 expression by 
Western blot. Poly I:C-treated IL-2-activated NK cells from TAK1fx/fx and Mx1Cre+TAK1fx/fx were 
analyzed for their effector functions. (B) NK cell-mediated cytotoxicity were tested against 51Cr-
labeled EL4 and EL4H60-High target cells at the indicated E:T ratios. (C) CD107a (LAMP1) surface 
expression in NK cells following plate-bound anti-NKG2D mAb-mediated activation. (D) Cytokine 
and chemokine production by NK cells following plate-bound anti-NKG2D mAb-mediated 
activation. (E) IL-12 and IL-18-mediated IFN-γ production in TAK1fx/fx and Mx1Cre+TAK1fx/fx-
derived NK cells.  (F) IFN-γ production by NK cells was determined by intracellular staining. 
Following anti-NKG2D mAb activation, NK cells were stained for surface expression of CD3 and 
NK1.1, fixed and permeabilized. These cells were stained for intracellular IFN-γ, gated for 
CD3−NK1.1+ cells and analyzed. (G) Anti-NKG2D-mediated IFN-γ gene transcription in TAK1fx/fx 
and Mx1Cre+TAK1fx/fx-derived NK cells. Data presented in A-G are representative of a minimum of 
three independent experiments. 
 
Fig. 6. Conditional knockdown of TAK1 impairs signaling downstream of NKG2D receptor in NK 
cells. Poly I:C-treated NK cells from TAK1fx/fx and Mx1Cre+TAK1fx/fx were activated with plate-
bound anti-NKG2D mAb and analyzed for signaling events downstream of NKG2D. (A) 
Phosphorylation of ERK1/2 and JNK1/2 following anti-NKG2D-mediated activation was analyzed 
through confocal microscopy.  (B) Average fluorescence intensity of phosphorylated and total 
ERK1/2 and JNK1/2 in TAK1fx/fx and Mx1Cre+TAK1fx/fx-derived NK cells were plotted and 
compared. Electrophoretic mobility shift assay (EMSA) to detect (C) NF-κB and (D) AP1 following 
anti-NKG2D mAb-mediated activation. (E) The fold changes in the nuclear translocation of NF-κB 
and AP1 in TAK1fx/fx and Mx1Cre+TAK1fx/fx-derived NK cells.  Data presented in A-E are 
representatives of a minimum of three independent experiments. 
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